Chemistry: analytical and immunological testing – Peptide – protein or amino acid – Glycoproteins
Reexamination Certificate
2008-09-02
2011-11-22
Prouty, Rebecca (Department: 1653)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
Glycoproteins
C436S817000
Reexamination Certificate
active
08062896
ABSTRACT:
The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor and further provides methods for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound.
REFERENCES:
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: 1 577 673 (2005-09-01), None
patent: 02/083913 (2002-10-01), None
patent: 02/089657 (2002-11-01), None
Olsen et al. N-Terminal Pro-Brain Natriuretic Peptide Predicts Cardiovascular Events in Patients With Hypertension and Left Ventricular Hypertrophy: A Life Study; Journal of Hypertension, vol. 22 (2004) pp. 1597-1604.
Sakhuja et al. NT-PROBNP—A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure; Business Briefing: US Cardiology (2004) pp. 1-5.
Giannitsis, E., Rationale for Testing the Cardiovascular Risk for Patients With COX-2 Inhibitors on the Basis of Biomarker NT-PROBNP; Clinical Laboratory, vol. 51, No. 1-2(2005) pp. 63-72.
Wells, et al., Additivity of Mutational Effects in Proteins; Biochemistry, vol. 29, No. 37 (1990) pp. 8509-8517.
Seffernick et al., Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical But Functionally Different; Journal of Bacteriology, vol. 183, No. 8 (2001) pp. 2405-2410.
Minter et al., The Clycooxygenase 2-Selective Inhibitor NS398 Inhibits Proliferation of Oralcarcinoma Cell Lines by Mechanisms Dependent and Independent of Reduced Protaglandin E2 Synthesis; Clinical Cancer Research, vol. 9 (2003) pp. 1885-1897.
Bibbins-Domingo et al., B-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease; Circulation, vol. 108 (2003) pp. 2987-2992.
Bombardier, Claire, et al., “Comparision of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” The New England Journal of Medicine, vol. 343, No. 21, Nov. 23, 2000, pp. 1709-1711.
Fitzgerald, Garret A. et al., “Coxibs and Cardiovascular Disease,” New England Journal of Medicine 351; 17, Oct. 21, 2004, pp. 1709-1711.
Juni, Peter et al., “Risk of cardiovascular events and rofecoxib: cumulative meta-analysis,” www.thelancet.com: vol. 364, Dec. 4, 2004, pp. 2021-2029.
Topol, Eric J. et al., “Failing the Public Health—Rofecoxib, Merk, and the FDA,” New England Journal of Medicine 331:17, Oct. 21, 2004, 1707-1709.
Mukherjee, Debabrata, et al., “Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors,” JAMA, Aug. 22/29, 2001—vol. 286, No. 8, pp. 954-959.
Ambrose, T., “Review of the Clinical Utility of NT-proBNP in the Diagnosis, Prognosis and Therapy Monitoring of Patients with Congestive Heart Failure,” Journal of Clinical Ligand Assay 25:2, Summer 2002, pp. 16-166.
Bazzino, O. et al., “Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostics classification and other risk markers in patients with non-ST-elevation acute coronary syndromes,” European Heart Journal (2004) 25, pp. 859-866.
Masson, S. et al., “Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure,” Clin. Chem. Lab Med 2002; 40(8) pp. 761-763.
Mamdani, M. et al., “Cyclo-oxygenase-2 Inhibitors Versus Non-Selective Non-Steroidal Anti-Inflammatory Drugs and Congestive Heart Failure Outcomes in Elderly Patients; a Population-based Cohort Study, ” The Lancet, vol. 363, May 29, 2004, pp. 1751-1756.
Pfister, R. et al., “Use of NT-proBNP in routine testing and comparison to BNP,” The European Journal of Heart Failure 6 (2004) pp. 289-293.
Ruskoaho, H., “Cardiac Hormones as Diagnostics Tools in Heart Failure,” Endocrine Reviews 2(3) pp. 341-356, 2003.
Martin Paul
Prouty Rebecca
Roche Diagnostics Operations Inc.
LandOfFree
Cardiac hormones for assessing cardiovascular risk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac hormones for assessing cardiovascular risk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac hormones for assessing cardiovascular risk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4310603